Beam Therapeutics
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
About
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines based on its proprietary base editing technology. This technology allows for precise, single-base changes in DNA and RNA without cutting the double helix, offering a new approach to treating genetic diseases by correcting specific mutations.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
Also in this space
Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.
Shares CRISPR, Biotech
Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.
Shares Biotech, MedTech
Developing gene editing therapies to lower cholesterol.
Shares Biotech, MedTech
Developing polymer-based nanoparticles for targeted gene therapy delivery.
Shares Biotech, MedTech
A clinical-stage biotechnology company developing in vivo gene editing therapies.
In Biotechnology
Cassidy Bio is an AI-driven company accelerating gene editing therapeutic development with bespoke solutions for faster, smarter R&D decisions.
Shares Workflow, Biotech
Key facts
- Website
- beamtherapeutics.com
- Headquarters
- Cambridge, United States
- Founded
- 2017
- Total funding
- $235M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Nov 2019 | Series C | $100M | Fidelity Investments |
| 1 Mar 2019 | Series B | $48M | Redmile Group |
| 14 May 2018 | Series A | $87M | F-Prime Capital, Arch Venture Partners, Eight Roads Ventures |
Frequently asked
How much funding has Beam Therapeutics raised?
Beam Therapeutics has raised a total of $235M in funding. The most recent round on record is Series C.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Beam Therapeutics
